Dynavax Technologies Corporation
- Biotech or pharma, therapeutic R&D
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The first being HEPLISAV-B, our adjuvanted hepatitis B vaccine for adults commercialized in the US and approved also in Europe and UK. Dynavax has a mid stage vaccines pipeline and is looking for later stage in-licensing/acquisition opportunities in the field of vaccines and infectious disease prevention and/or therapy.
Dynavax also owns its CpG1018 adjuvant which, on top of being utlized in Heplisav B, has been used in 5 approved COVID vaccines around the world. Dynavax is keen to make its CpG1018 adjuvant available for collaboration and/or licensing to interested parties.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}